TY - JOUR
T1 - Clinician Conceptualization of the Benefits of Treatments for Individual Patients
AU - Morgan, Daniel J.
AU - Pineles, Lisa
AU - Owczarzak, Jill
AU - Magder, Larry
AU - Scherer, Laura
AU - Brown, Jessica P.
AU - Pfeiffer, Chris
AU - Terndrup, Chris
AU - Leykum, Luci
AU - Feldstein, David
AU - Foy, Andrew
AU - Stevens, Deborah
AU - Koch, Christina
AU - Masnick, Max
AU - Weisenberg, Scott
AU - Korenstein, Deborah
N1 - Funding Information:
Funding/Support: This project was funded by New Innovator Award DP2LM012890 from the National Institutes of Health National Library of Medicine to Dr Morgan.
Funding Information:
Administrative, technical, or material support: Morgan, Pineles, Owczarzak, Scherer, Terndrup, Stevens, Koch. Supervision: Morgan. Conflict of Interest Disclosures: Dr Morgan reported receiving grants from Veterans Affairs, the Agency for Healthcare Research and Quality, and the US Centers for Disease Control and Prevention and receiving travel reimbursement for conference speaking or coordination from the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, and the Lown Institute outside the submitted work. Dr Scherer reported receiving grants from the Agency for Healthcare Research and Quality during the conduct of the study. Dr Brown reported receiving grants from the National Institutes of Health outside the submitted work. Dr Pfeiffer reported receiving grants from Pfizer outside the submitted work. Dr Feldstein reported receiving an honorarium from the University of Maryland–Baltimore during the conduct of the study. Dr Korenstein reported that their spouse serves on the scientific advisory board of and has equity interest in Vedanta Biosciences, serves on the scientific advisory board of the Pandemic Response Lab–NYC, and provides consulting for Fibrion. No other disclosures were reported.
Publisher Copyright:
© 2015 Future Medicine Ltd.. All rights reserved.
PY - 2021/7/21
Y1 - 2021/7/21
N2 - Importance: Knowing the expected effect of treatment on an individual patient is essential for patient care. Objective: To explore clinicians' conceptualizations of the chance that treatments will decrease the risk of disease outcomes. Design, Setting, and Participants: This survey study of attending and resident physicians, nurse practitioners, and physician assistants was conducted in outpatient clinical settings in 8 US states from June 2018 to November 2019. The survey was an in-person, paper, 26-item survey in which clinicians were asked to estimate the probability of adverse disease outcomes and expected effects of therapies for diseases common in primary care. Main Outcomes and Measures: Estimated chance that treatments would benefit an individual patient. Results: Of 723 clinicians, 585 (81%) responded, and 542 completed all the questions necessary for analysis, with a median (interquartile range [IQR]) age of 32 (29-44) years, 287 (53%) women, and 294 (54%) White participants. Clinicians consistently overestimated the chance that treatments would benefit an individual patient. The median (IQR) estimated chance that warfarin would prevent a stroke in the next year was 50% (5%-80%) compared with scientific evidence, which indicates an absolute risk reduction (ARR) of 0.2% to 1.0% based on a relative risk reduction (RRR) of 39% to 50%. The median (IQR) estimated chance that antihypertensive therapy would prevent a cardiovascular event within 5 years was 30% (10%-70%) vs evidence of an ARR of 0% to 3% based on an RRR of 0% to 28%. The median (IQR) estimated chance that bisphosphonate therapy would prevent a hip fracture in the next 5 years was 40% (10%-60%) vs evidence of ARR of 0.1% to 0.4% based on an RRR of 20% to 40%. The median (IQR) estimated chance that moderate-intensity statin therapy would prevent a cardiovascular event in the next 5 years was 20% (IQR 5%-50%) vs evidence of an ARR of 0.3% to 2% based on an RRR of 19% to 33%. Estimates of the chance that a treatment would prevent an adverse outcome exceeded estimates of the absolute chance of that outcome for 60% to 70% of clinicians. Clinicians whose overestimations were greater were more likely to report using that treatment for patients in their practice (eg, use of warfarin: correlation coefficient, 0.46; 95% CI, 0.40-0.53; P <.001). Conclusions and Relevance: In this survey study, clinicians significantly overestimated the benefits of treatment to individual patients. Clinicians with greater overestimates were more likely to report using treatments in actual patients.
AB - Importance: Knowing the expected effect of treatment on an individual patient is essential for patient care. Objective: To explore clinicians' conceptualizations of the chance that treatments will decrease the risk of disease outcomes. Design, Setting, and Participants: This survey study of attending and resident physicians, nurse practitioners, and physician assistants was conducted in outpatient clinical settings in 8 US states from June 2018 to November 2019. The survey was an in-person, paper, 26-item survey in which clinicians were asked to estimate the probability of adverse disease outcomes and expected effects of therapies for diseases common in primary care. Main Outcomes and Measures: Estimated chance that treatments would benefit an individual patient. Results: Of 723 clinicians, 585 (81%) responded, and 542 completed all the questions necessary for analysis, with a median (interquartile range [IQR]) age of 32 (29-44) years, 287 (53%) women, and 294 (54%) White participants. Clinicians consistently overestimated the chance that treatments would benefit an individual patient. The median (IQR) estimated chance that warfarin would prevent a stroke in the next year was 50% (5%-80%) compared with scientific evidence, which indicates an absolute risk reduction (ARR) of 0.2% to 1.0% based on a relative risk reduction (RRR) of 39% to 50%. The median (IQR) estimated chance that antihypertensive therapy would prevent a cardiovascular event within 5 years was 30% (10%-70%) vs evidence of an ARR of 0% to 3% based on an RRR of 0% to 28%. The median (IQR) estimated chance that bisphosphonate therapy would prevent a hip fracture in the next 5 years was 40% (10%-60%) vs evidence of ARR of 0.1% to 0.4% based on an RRR of 20% to 40%. The median (IQR) estimated chance that moderate-intensity statin therapy would prevent a cardiovascular event in the next 5 years was 20% (IQR 5%-50%) vs evidence of an ARR of 0.3% to 2% based on an RRR of 19% to 33%. Estimates of the chance that a treatment would prevent an adverse outcome exceeded estimates of the absolute chance of that outcome for 60% to 70% of clinicians. Clinicians whose overestimations were greater were more likely to report using that treatment for patients in their practice (eg, use of warfarin: correlation coefficient, 0.46; 95% CI, 0.40-0.53; P <.001). Conclusions and Relevance: In this survey study, clinicians significantly overestimated the benefits of treatment to individual patients. Clinicians with greater overestimates were more likely to report using treatments in actual patients.
UR - http://www.scopus.com/inward/record.url?scp=85111443434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111443434&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2021.19747
DO - 10.1001/jamanetworkopen.2021.19747
M3 - Article
C2 - 34287630
AN - SCOPUS:85111443434
SN - 2574-3805
VL - 4
JO - JAMA network open
JF - JAMA network open
IS - 7
M1 - 19747
ER -